Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential?

Vera Therapeutics Inc. (NASDAQ:VERA) is one of the best high short interest stocks with biggest upside potential. Earlier on December 19, Bank of America raised its price target for Vera Therapeutics from $48 to $66 while maintaining a Buy rating due to an increased peak revenue forecast for its lead IgAN drug from $1.7 billion to $2.2 billion. This upward revision stemmed from higher expected pricing based on class competitors and a strengthened net cash position of $680 million following a recent equity raise, which the firm believes positions Vera Therapeutics for a robust commercial launch in mid-2026.

On the same day, Goldman Sachs increased its price target for Vera Therapeutics from $55 to $95 with a Buy rating in light of a substantially expanded TAM. The revision followed the FDA approval and premium pricing of Otsuka’s Voyxact, which suggested much higher pricing potential for the APRIL/BAFF inhibitor class in treating IgAN than previously anticipated.

Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential?

Furthermore, JPMorgan adjusted its price target for Vera Therapeutics Inc. (NASDAQ:VERA) to $96 from $99 with an Overweight rating on the stock following a broader model update across the firm’s small-to-mid-cap biotech coverage group.

Vera Therapeutics Inc. (NASDAQ:VERA) is a clinical-stage biotech company that develops and commercializes transformative treatments for patients with serious immunological diseases.

While we acknowledge the potential of VERA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VERA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.